Literature DB >> 18595767

The 6-hydroxydopamine model: news from the past.

Fabio Blandini1, Marie-Therese Armentero, Emilia Martignoni.   

Abstract

The investigation of pathogenic and pathophysiological mechanisms of Parkinson's disease relies on experimental models reproducing, in the animal, the pathological and behavioural features of the disease. Despite the availability of innovative models, 6-hydroxydopamine (6-OHDA) remains the most widely used tool to induce a nigrostriatal lesion in the animal (rat). This is due to (1) the relatively low complexity and cost of the procedure, (2) the fact that the 6-OHDA-induced lesion is highly reproducible, and (3) the versatility of the procedure, which can yield varying degrees of nigrostriatal lesions that develop with different temporal profiles, depending on the site chosen for the toxin injection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18595767     DOI: 10.1016/j.parkreldis.2008.04.015

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  92 in total

1.  6-OHDA induces cycle reentry and apoptosis of PC12 cells through activation of ERK1/2 signaling pathway.

Authors:  Zhentao Zhang; Tao Wang; Xuebing Cao; Shenggang Sun; Lan Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-02-18

2.  Carvedilol attenuates 6-hydroxydopamine-induced cell death in PC12 cells: involvement of Akt and Nrf2/ARE pathways.

Authors:  Lan Wang; Rikang Wang; Minghua Jin; Yingjuan Huang; Anmin Liu; Jian Qin; Meihui Chen; Shijun Wen; Rongbiao Pi; Wei Shen
Journal:  Neurochem Res       Date:  2014-06-21       Impact factor: 3.996

3.  Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: potential relevance to the pathophysiology of Parkinson's disease.

Authors:  Roberto Cosimo Melcangi; Donatella Caruso; Giovanna Levandis; Federico Abbiati; Marie-Therese Armentero; Fabio Blandini
Journal:  J Mol Neurosci       Date:  2011-06-14       Impact factor: 3.444

4.  L-F001, a Multifunction ROCK Inhibitor Prevents 6-OHDA Induced Cell Death Through Activating Akt/GSK-3beta and Nrf2/HO-1 Signaling Pathway in PC12 Cells and Attenuates MPTP-Induced Dopamine Neuron Toxicity in Mice.

Authors:  Liting Luo; Jingkao Chen; Dan Su; Meihui Chen; Bingling Luo; Rongbiao Pi; Lan Wang; Wei Shen; Rikang Wang
Journal:  Neurochem Res       Date:  2017-01-11       Impact factor: 3.996

5.  Treadmill Exercise Prevents Increase of Neuroinflammation Markers Involved in the Dopaminergic Damage of the 6-OHDA Parkinson's Disease Model.

Authors:  Caroline Cristiano Real; Priscila Crespo Garcia; Luiz R G Britto
Journal:  J Mol Neurosci       Date:  2017-08-11       Impact factor: 3.444

6.  Inhibition of Mitochondrial Clearance and Cu/Zn-SOD Activity Enhance 6-Hydroxydopamine-Induced Neuronal Apoptosis.

Authors:  Sua In; Chang-Won Hong; Boyoung Choi; Bong-Geum Jang; Min-Ju Kim
Journal:  Mol Neurobiol       Date:  2015-01-29       Impact factor: 5.590

7.  Antioxidant effect of Spirulina (Arthrospira) maxima in a neurotoxic model caused by 6-OHDA in the rat striatum.

Authors:  J C Tobón-Velasco; Victoria Palafox-Sánchez; Liliana Mendieta; E García; A Santamaría; G Chamorro-Cevallos; I Daniel Limón
Journal:  J Neural Transm (Vienna)       Date:  2013-02-21       Impact factor: 3.575

Review 8.  Solvents and Parkinson disease: a systematic review of toxicological and epidemiological evidence.

Authors:  Edward A Lock; Jing Zhang; Harvey Checkoway
Journal:  Toxicol Appl Pharmacol       Date:  2012-12-07       Impact factor: 4.219

9.  Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease.

Authors:  J A Morales-García; C Susín; S Alonso-Gil; D I Pérez; V Palomo; C Pérez; S Conde; A Santos; C Gil; A Martínez; A Pérez-Castillo
Journal:  ACS Chem Neurosci       Date:  2012-12-05       Impact factor: 4.418

10.  Neuroprotective Effects of Paeoniflorin on 6-OHDA-Lesioned Rat Model of Parkinson's Disease.

Authors:  Xiao-Su Gu; Fen Wang; Cai-Yi Zhang; Cheng-Jie Mao; Jing Yang; Ya-Ping Yang; Sha Liu; Li-Fang Hu; Chun-Feng Liu
Journal:  Neurochem Res       Date:  2016-07-22       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.